ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial

Eli Lilly announced retatrutide's trial results at ESC 2024, showing it reduced non-HDL-C, apoB, triglycerides, and improved lipid profiles in obese patients, potentially revolutionizing obesity treatment.